CL2008000280A1 - Composicion farmaceutica en forma de comprimido que contiene un granulo que comprende un principio activo que induce facilmente a un problema en la compresion y celulosa microcristalina y un auxiliar de compresion que contiene estearato de magnesio y - Google Patents

Composicion farmaceutica en forma de comprimido que contiene un granulo que comprende un principio activo que induce facilmente a un problema en la compresion y celulosa microcristalina y un auxiliar de compresion que contiene estearato de magnesio y

Info

Publication number
CL2008000280A1
CL2008000280A1 CL200800280A CL2008000280A CL2008000280A1 CL 2008000280 A1 CL2008000280 A1 CL 2008000280A1 CL 200800280 A CL200800280 A CL 200800280A CL 2008000280 A CL2008000280 A CL 2008000280A CL 2008000280 A1 CL2008000280 A1 CL 2008000280A1
Authority
CL
Chile
Prior art keywords
compression
granulum
microcrystaline
cellulose
pharmaceutical composition
Prior art date
Application number
CL200800280A
Other languages
English (en)
Inventor
Ono Shigeyuki Marunaka Akihiko
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000280(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CL2008000280A1 publication Critical patent/CL2008000280A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL200800280A 2007-02-01 2008-01-30 Composicion farmaceutica en forma de comprimido que contiene un granulo que comprende un principio activo que induce facilmente a un problema en la compresion y celulosa microcristalina y un auxiliar de compresion que contiene estearato de magnesio y CL2008000280A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007023584 2007-02-01

Publications (1)

Publication Number Publication Date
CL2008000280A1 true CL2008000280A1 (es) 2008-08-18

Family

ID=39156227

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800280A CL2008000280A1 (es) 2007-02-01 2008-01-30 Composicion farmaceutica en forma de comprimido que contiene un granulo que comprende un principio activo que induce facilmente a un problema en la compresion y celulosa microcristalina y un auxiliar de compresion que contiene estearato de magnesio y

Country Status (11)

Country Link
US (1) US8697125B2 (es)
EP (1) EP2124901B1 (es)
JP (1) JP5284967B2 (es)
AR (1) AR065096A1 (es)
CA (1) CA2677193C (es)
CL (1) CL2008000280A1 (es)
ES (1) ES2639854T3 (es)
HR (1) HRP20171518T1 (es)
PE (1) PE20081734A1 (es)
TW (1) TW200836774A (es)
WO (1) WO2008093878A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
JP5432720B2 (ja) * 2007-03-13 2014-03-05 武田薬品工業株式会社 ２−［［６−［（３ｒ）−３−アミノ−１−ピペリジニル］−３，４−ジヒドロ−３−メチル−２，４−ジオキソ−１（２ｈ）−ピリミジニル］メチル］−４−フルオロベンゾニトリルを含む固形製剤
AR067557A1 (es) * 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102264719A (zh) * 2008-12-23 2011-11-30 桑多斯股份公司 结晶形式的有机化合物
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
MX339194B (es) 2009-02-13 2016-05-16 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
WO2010092163A2 (en) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
CN102548556A (zh) * 2009-07-28 2012-07-04 武田药品工业株式会社 片剂
EP3566697B1 (en) * 2009-11-09 2024-09-11 Wyeth LLC Tablet formulations of neratinib maleate
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
CN102711761B (zh) * 2009-12-18 2015-06-03 田边三菱制药株式会社 溶出稳定化制剂
JP5787881B2 (ja) * 2010-04-30 2015-09-30 武田薬品工業株式会社 腸溶性錠剤
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
JP5874545B2 (ja) * 2011-06-20 2016-03-02 アステラス製薬株式会社 経口投与用医薬組成物
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
KR20150059720A (ko) * 2012-09-27 2015-06-02 가부시키가이샤산와카가쿠켄큐쇼 아나글립틴 함유 제제
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN103610661B (zh) * 2013-11-22 2017-09-12 威海迪素制药有限公司 一种组合物
CN104721188A (zh) * 2013-12-20 2015-06-24 中美华世通生物医药科技（武汉）有限公司 一种稳定的含苯甲酸阿格列汀的组合物
JP6238921B2 (ja) * 2014-02-17 2017-11-29 大原薬品工業株式会社 イルベサルタンを含有する錠剤
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US10548848B2 (en) 2015-06-17 2020-02-04 Hexal Ag Alogliptin formulation
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
JP7250305B2 (ja) * 2018-10-02 2023-04-03 共和薬品工業株式会社 メマンチン又はその薬物学的に許容される塩を含む医薬組成物及びその製造方法
JP7340572B2 (ja) * 2021-08-20 2023-09-07 セトラスホールディングス株式会社 酸化マグネシウム錠剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200193A (en) 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
JP3836528B2 (ja) * 1995-11-17 2006-10-25 エスエス製薬株式会社 イブプロフェン含有錠剤及びその製造法
AU718030B2 (en) 1996-05-20 2000-04-06 G.D. Searle & Co. Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
US6348216B1 (en) * 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
JPH1059842A (ja) 1996-08-13 1998-03-03 Lion Corp 錠剤用組成物及び打錠方法
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
EP0998272B1 (en) 1997-08-26 2003-05-02 Aventis Pharmaceuticals Inc. Pharmaceutical composition for combination of piperidinoalkanol-decongestant
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
HRP20010582A2 (en) 1999-12-08 2002-08-31 Pharmacia Corp Valdecoxib compositions
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
JP2002179559A (ja) * 2000-10-06 2002-06-26 Takeda Chem Ind Ltd 薄層糖衣錠およびその製造方法
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
JP2004189653A (ja) 2002-12-10 2004-07-08 Yoshio Itabashi イブプロフェン含有錠剤
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
JP5122144B2 (ja) * 2004-01-20 2013-01-16 ノバルティス アーゲー 直接圧縮製剤および方法
CN102079743B (zh) * 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
DE202006000591U1 (de) 2005-01-20 2006-03-30 Analyze & Realize Ag Gelenkformulierung
EP1906936A2 (en) 2005-05-18 2008-04-09 Combino Pharm, S.L. Formulations containing losartan and/or its salts
GEP20135791B (en) 2005-09-14 2013-03-25 Takeda Pharmaceutical Use of dipeptidyl peptidase inhibitors
TW200745079A (en) 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
WO2007078726A2 (en) * 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin

Also Published As

Publication number Publication date
JP5284967B2 (ja) 2013-09-11
EP2124901B1 (en) 2017-07-19
EP2124901A1 (en) 2009-12-02
ES2639854T3 (es) 2017-10-30
CA2677193C (en) 2015-06-30
WO2008093878A1 (en) 2008-08-07
US8697125B2 (en) 2014-04-15
AR065096A1 (es) 2009-05-13
CA2677193A1 (en) 2008-08-07
TW200836774A (en) 2008-09-16
JP2010517936A (ja) 2010-05-27
HRP20171518T1 (hr) 2017-11-17
PE20081734A1 (es) 2009-01-19
US20090318482A1 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
FR25C1035I1 (fr) Formulations de comprimés de maléate de nératinib
HRP20181819T1 (hr) Formulacija krutog farmaceutskog oblika doziranja koja sadrži lopinavir
BRPI0912161A2 (pt) composição farmacêutica na forma de um tablete
IL192773A0 (en) Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol
DK2343071T3 (da) Farmaceutiske doseringsformer
BRPI0811303A2 (pt) Formulação de comprimido de desintegranção rápida robusta
EP2012773A4 (en) ACTIVE SUBSTANCES AND THEIR APPLICATIONS
DK3345625T3 (da) Farmaceutisk sammensætning og indgivelser deraf
EP2068887A4 (en) SP35 ANTIBODY AND ITS USE
EP2367570A4 (en) ANTIBODIES TO IL-6 AND THEIR USE
BRPI0812337A2 (pt) Agente de benefício contendo partícula de liberação
EP2255809A4 (en) PLASTER WITH MEDICAMENT PLASTER
EP2124548A4 (en) DISINTEGRIN VARIANTS AND PHARMACEUTICAL USES THEREOF
DE602006004731D1 (de) Trockengranulierungzusammensetzung enthaltend Emtricitabine und Tenofovir DF
ZA201009004B (en) Orally administrable dosage forms comprising angiogenin and uses thereof
EP2474522A4 (en) AGOME ELITE AND PHARMACEUTICAL COMPOSITIONS THEREOF
HUE043897T2 (hu) Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra
DK3181691T3 (da) Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme
GB0817701D0 (en) Krill oil powder and krill oil tablets
IL210937A (en) New phenyl – amino isonicotinamide compounds and their use
IL223012B (en) Pharmacy preparations in the form of tablets with two layers containing atorvastatin and irbesartan
GB0602906D0 (en) Use of location awareness to facilitate clinician-charger interaction in a healthcare environment
EP2341047A4 (en) CYCLOHEXANDERIVATE AND PHARMACEUTICAL USE THEREOF
EP1922679A4 (en) DYNAMIC MODELING OF HEALTH CARE
IL181150A0 (en) Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle